<DOC>
	<DOCNO>NCT01538225</DOCNO>
	<brief_summary>Aim randomize , double-blind , placebo-controlled , cross-over study investigate cannabinoid-induced change neurophysiological parameter group 40 patient secondary primary progressive Multiple Sclerosis ( MS ) .</brief_summary>
	<brief_title>Neurophysiological Study Sativex Multiple Sclerosis ( MS ) Spasticity</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Muscle Spasticity</mesh_term>
	<criteria>Aged 18 year Willing able comply protocol duration study Diagnosis SecondaryProgressive PrimaryProgressive MS least 12 month Relapse free least 3 month screen visit Lower limb spasticity EDSS &gt; 3.0 &lt; 6.5 Moderate severe spasticity due MS least 6 month stable drug treatment able relieve symptom whole , deserve specific addon treatment Immunomodulatory immunosuppressant therapy modify study 6 month start study Stable dos antispasticity agent least 2 month prior screen visit Have give write informed consent Any concomitant disease may cause spasticity could interfere subject 's spasticity Botulinum Toxin injection spasticity 4 month prior screen visit Any know suspected history psychotic illness , alcohol substance abuse , epilepsy , hypersensitivity cannabinoids Significant cardiac , renal hepatic disease Female subject child bearing potential male subject whose partner child bear potential , unless willing ensure partner use contraception study Female subject pregnant lactate planning pregnancy course study three month thereafter SativexÂ® SmPC contraindication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Spasticity</keyword>
</DOC>